ANRO Alto Neuroscience Inc.

  1. Stocks
  2. Healthcare
  3. NYSE: ANRO

Price (delayed)

$19.8

Market cap

$694.86M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.42

Enterprise value

$452.51M

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Building on more than a decade of ...

Highlights
ANRO's equity has soared by 75% YoY and by 61% QoQ
The debt has declined by 14% year-on-year and by 3.9% since the previous quarter
ANRO's quick ratio is up by 29% since the previous quarter but it is down by 9% year-on-year
The company's net income fell by 18% YoY and by 18% QoQ
The EPS has declined by 11% since the previous quarter and by 3.4% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: https://www.altoneuroscience.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of ANRO

ANRO stock price

How has the Alto Neuroscience stock price performed over time
Intraday
5.04%
1 week
-2.08%
1 month
-21.4%
1 year
708.16%
YTD
11.24%
QTD
-11.92%

Financial performance

How have Alto Neuroscience's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$77.83M
Net income
-$74.31M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 18% YoY and by 18% QoQ
Alto Neuroscience's operating income has decreased by 17% QoQ and by 11% YoY

Price vs fundamentals

How does ANRO's price correlate with its fundamentals

Growth

What is Alto Neuroscience's growth rate over time

Valuation

What is Alto Neuroscience stock price valuation
P/E
N/A
P/B
2.6
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 11% since the previous quarter and by 3.4% year-on-year
ANRO's equity has soared by 75% YoY and by 61% QoQ
The price to book (P/B) is 24% more than the last 4 quarters average of 2.0

Efficiency

How efficient is Alto Neuroscience business performance
Alto Neuroscience's ROIC has decreased by 29% from the previous quarter but it has increased by 26% YoY
The ROE has decreased by 19% YoY but it has increased by 2.1% QoQ
The return on assets has declined by 13% year-on-year

Dividends

What is ANRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANRO.

Financial health

How did Alto Neuroscience financials performed over time
ANRO's total assets has surged by 61% year-on-year and by 50% since the previous quarter
ANRO's current ratio is up by 31% since the previous quarter but it is down by 9% year-on-year
The debt is 91% smaller than the equity
ANRO's equity has soared by 75% YoY and by 61% QoQ
ANRO's debt to equity has plunged by 50% YoY and by 40% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.